MedTrace Logo

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

NCT05321979 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2024-01-16

No results posted yet for this study

Summary

This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.

Conditions

  • Glabellar Frown Lines

Interventions

DRUG

MBA-P01

MBA-P01 will be injected into the Glabellar line.

Sponsors & Collaborators

  • Medytox Korea

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2023-05-30
Completion
2023-05-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321979 on ClinicalTrials.gov